Skip to main content

TSHA

Stock
Health Care
Biotechnology

Performance overview

TSHA Price
Price Chart

Forward-looking statistics

Beta
—
Risk
—

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Company info

SectorHealth Care
IndustryBiotechnology
Employees74
Market cap$738.7M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth-7.5
Credit+15.7
Liquidity+4.5
Inflation-16.4
Commodities-1.1
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-6.43
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day—
Ex. dividend day—

News

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

Taysha Gene Therapies Inc.  TSHA on Wednesday announced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the U.S. Food and Drug Administration (FDA).

Benzinga (May 29, 2025)
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.

Zacks Investment Research (May 15, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free